Patents by Inventor Alexander Alexei Greenfield

Alexander Alexei Greenfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7790751
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: September 7, 2010
    Assignee: Wyeth LLC
    Inventors: Hassan Mahmoud Elokdah, Alexander Alexei Greenfield, Kevin Liu, Geraldine Ruth McFarlane, Cristina Grosanu, Jennifer Rebecca Lo, Albert Jean Robichaud
  • Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7723329
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: May 25, 2010
    Assignee: Wyeth LLC
    Inventors: Hassan Mahmoud Elokdah, Alexander Alexei Greenfield, Kevin Liu, Robert Emmett McDevitt, Geraldine Ruth McFarlane, Cristina Grosanu, Jennifer Rebecca Lo, Yanfang Li, Albert Jean Robichaud, Ronald Charles Bernotas
  • DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20080280894
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: July 15, 2008
    Publication date: November 13, 2008
    Applicant: Wyeth
    Inventors: Alexander Alexei Greenfield, Cristina Grosanu, Hassan Mahmoud Elokdah, Albert Jean Robichaud
  • SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20080280893
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: July 14, 2008
    Publication date: November 13, 2008
    Applicant: Wyeth
    Inventors: Hassan Mahmoud Elokdah, Alexander Alexei Greenfield, Cristina Grosanu, Albert Jean Robichaud
  • Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders
    Patent number: 7429582
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: September 30, 2008
    Assignee: Wyeth
    Inventors: Alexander Alexei Greenfield, Cristina Grosanu, Hassan Mahmoud Elokdah, Albert Jean Robichaud
  • Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7414051
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: August 19, 2008
    Assignee: Wyeth
    Inventors: Hassan Mahmoud Elokdah, Alexander Alexei Greenfield, Cristina Grosanu, Albert Jean Robichaud
  • Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20070244106
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 11, 2007
    Publication date: October 18, 2007
    Applicant: Wyeth
    Inventors: Hassan Mahmoud Elokdah, Alexander Alexei Greenfield, Cristina Grosanu, Albert Jean Robichaud
  • Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20070244179
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 11, 2007
    Publication date: October 18, 2007
    Applicant: Wyeth
    Inventors: Alexander Alexei Greenfield, Cristina Grosanu, Hassan Mahmoud Elokdah, Albert Jean Robichaud
  • Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
    Publication number: 20070244105
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 11, 2007
    Publication date: October 18, 2007
    Applicant: Wyeth
    Inventors: Alexander Alexei Greenfield, Cristina Grosanu, Hassan Mahmoud Elokdah, Albert Jean Robichaud
  • Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport
    Patent number: 6750364
    Abstract: This invention provides compounds of the formula: wherein X is (CH2)n, O, S, SO, SO2 or CR1R2; n is 1 or 2; R1 and R2 are H, halogen, hydroxy, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or R1 and R2, taken together form cycloalkyl of 3 to 6 carbon atoms, an alkylidene of up to 6 carbon atoms or a carbonyl; R3, R4 and R5 are H or alkyl of 1 to 6 carbon atoms; Z is H, alkyl of 1 to 6 carbon atoms, alkanoyl of 1 to 6 carbon atoms or alkoxycarbonyl of 2 to 7 carbon atoms; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods for their use in treating or preventing characterized by glutamate hypofunction, including schizophrenia, schizoaffective disorder and schizophreniform disorder, and for the treatment of cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: June 15, 2004
    Assignee: Wyeth
    Inventors: Gary Paul Stack, John Dunlop, Alexander Alexei Greenfield, Jonathan Laird Gross
  • Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
    Patent number: 6689904
    Abstract: This invention provides processes for preparing a group of novel bridged tricyclic compounds having the formula: wherein X is (CH2)n, O, S, SO, SO2 or CR1R2; n is 1 or 2; and R1 and R2 are, independently, hydrogen, halogen, hydroxy, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, or R1 and R2, taken together with the carbon to which they are attached, form cycloalkyl of three to six carbon atoms, an alkylidene of up to six carbon atoms or a carbonyl.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: February 10, 2004
    Assignee: Wyeth
    Inventors: Alexander Alexei Greenfield, John Anthony Butera
  • Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport
    Publication number: 20030022930
    Abstract: This invention provides compounds of the formula: 1
    Type: Application
    Filed: June 27, 2002
    Publication date: January 30, 2003
    Applicant: Wyeth
    Inventors: Gary Paul Stack, John Dunlop, Alexander Alexei Greenfield, Jonathan Laird Gross
  • Bridged tricyclid analogs of 2-(carboxycyclopropyl)glycine
    Publication number: 20030018065
    Abstract: This invention provides processes for preparing a group of novel bridged tricyclic compounds having the formula: 1
    Type: Application
    Filed: June 27, 2002
    Publication date: January 23, 2003
    Applicant: Wyeth
    Inventors: Alexander Alexei Greenfield, John Anthony Butera